Paterna Biosciences

Executive Summary

Paterna Biosciences is a private, preclinical-stage biotechnology company headquartered in San Diego, California, founded in 2018. The company is dedicated to discovering and developing novel targeted therapies for oncology and immune-related diseases, aiming to address significant unmet medical needs. While specific pipeline details are not publicly disclosed, Paterna's research efforts are focused on leveraging innovative approaches to modulate immune responses and target cancer cells. As a preclinical entity, the company has not yet initiated clinical trials and operates with limited public information, making its near-term prospects highly speculative. However, its focus on high-need therapeutic areas positions it as a potential candidate for partnerships or further investment upon achieving key preclinical milestones.

Upcoming Catalysts (preview)

• TBDIND Filing for Lead Candidate30% success
• Q4 2026Series A or B Financing Round50% success
• Q3 2026Publication of Preclinical Data in Peer-Reviewed Journal60% success